Leerink Partnrs Has Positive Estimate for REGN Q3 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Analysts at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a report issued on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $7.77 per share for the quarter, up from their previous forecast of $7.64. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ FY2025 earnings at $31.96 EPS.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. During the same quarter last year, the company earned $11.56 earnings per share. The firm’s revenue was up 3.6% on a year-over-year basis.

A number of other research analysts have also commented on REGN. Sanford C. Bernstein upped their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley reiterated an “overweight” rating and set a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Finally, Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $600.00 on Thursday. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $1,038.81. The company has a market capitalization of $63.59 billion, a P/E ratio of 15.12, a P/E/G ratio of 1.92 and a beta of 0.31. The stock has a 50 day moving average of $571.38 and a two-hundred day moving average of $568.39. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of REGN. Brighton Jones LLC lifted its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 686 shares during the period. NBC Securities Inc. bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $78,000. Merit Financial Group LLC lifted its position in Regeneron Pharmaceuticals by 87.7% during the 1st quarter. Merit Financial Group LLC now owns 1,629 shares of the biopharmaceutical company’s stock valued at $1,033,000 after purchasing an additional 761 shares during the period. Whipplewood Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3,220.0% in the 1st quarter. Whipplewood Advisors LLC now owns 166 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 161 shares during the last quarter. Finally, Portside Wealth Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 7.6% in the 1st quarter. Portside Wealth Group LLC now owns 776 shares of the biopharmaceutical company’s stock valued at $492,000 after purchasing an additional 55 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.